Related Experiment Video
Updated: Jul 1, 2025
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
Published on: May 16, 2012
The value of a panel of circulating microRNAs in screening prostate cancer
Chen Sun1,2, Chong Lu1,2, Xinji Li1,3
1Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, the fifth Clinical Medical College of Anhui Medical University, Shenzhen, China.
Background:
Prostate cancer (PCa) remains a worldwide public health problem that poses a serious threat to the health of men worldwide. Many studies have found that microRNA (miRNA) in serum has the potential to be a biomarker for cancer screening. Our study was conducted to investigate the value of serum miRNAs in PCa screening.
Methods:
We selected 12 miRNAs from past studies for its association with PCa. We checked the expression levels of these miRNAs in the serum of 112 PCa patients and 112 healthy controls in a two-stage experiment. We plotted the receiver operating characteristic curve of miRNAs in the validation stage and constructed a four-miRNA panel with the highest diagnostic value using stepwise logistic regression. We also predicted the target genes with these four miRNAs through online databases and performed Gene Ontology functional annotation and pathway analysis.
Results:
The results showed that six miRNAs (miR-429, miR-10a-5p, miR-183-5p, miR-181a-5p, miR-1231, miR-129-5p) were abnormally expressed in the serum of PCa patients. We used four of these miRNAs including miR-1231, miR-10a-5p, miR-429 and miR-129-5p to construct a combination of miRNAs with high specificity and sensitivity in screening PCa (area under the curve =0.878). Bioinformatics analysis showed that the genes targeted by these miRNAs can be linked to the development of PCa.
Conclusions:
Our study detected and identified a set of miRNAs that serves as screening marker for PCa, which may assist in early diagnosis and treatment of PCa.
Insights
This study identifies specific microRNAs (miRNAs) in blood that can help screen for prostate cancer (PCa). A panel of four miRNAs shows high accuracy for early PCa detection.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Prostate cancer (PCa) is a significant global health concern for men.
- Serum microRNAs (miRNAs) show promise as potential biomarkers for cancer screening.
- This research investigated the utility of serum miRNAs for PCa screening.
Purpose of the Study:
- To evaluate the diagnostic value of specific serum miRNAs in prostate cancer detection.
- To identify a panel of miRNAs with high sensitivity and specificity for PCa screening.
- To explore the role of miRNA target genes in prostate cancer development.
Main Methods:
- Selected 12 miRNAs previously associated with PCa.
- Quantified miRNA expression in serum from 112 PCa patients and 112 healthy controls across two stages.
- Developed a four-miRNA diagnostic panel using logistic regression and validated its performance with ROC curve analysis.
Main Results:
- Six miRNAs (miR-429, miR-10a-5p, miR-183-5p, miR-181a-5p, miR-1231, miR-129-5p) exhibited altered expression in PCa patients' serum.
- A four-miRNA panel (miR-1231, miR-10a-5p, miR-429, miR-129-5p) achieved an area under the curve of 0.878 for PCa screening.
- Bioinformatics analysis linked the target genes of these miRNAs to PCa pathogenesis.
Conclusions:
- Identified a set of serum miRNAs as effective screening markers for prostate cancer.
- The developed miRNA panel demonstrates high specificity and sensitivity for PCa detection.
- These findings may aid in the early diagnosis and treatment of prostate cancer.
